Emerging data on improving response to hormone therapy: the role of novel targeted agents

References

• Yue W, Fan P, Wang J, et al. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1–5):102–110. PubMed PMID: 17616457; PubMed Central PMCID: PMCPMC2147683. eng. DOI:10.1016/j.jsbmb.2007.05.008
   PubMed Web of Science ®Google Scholar
• Cortes J, Im SA, Holgado E, et al. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: triplet combination-based endocrine therapies. Cancer Treat Rev. 2017 Dec;61:53–60. PubMed PMID: 29100169; eng. DOI:10.1016/j.ctrv.2017.09.011
   PubMed Web of Science ®Google Scholar
• Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2014 Apr 1;20(7):1757–1767. PubMed PMID: 24398047; PubMed Central PMCID: PMCPMC3998833. eng. DOI:10.1158/1078-0432.ccr-13-2332
   PubMed Web of Science ®Google Scholar
• Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013 Dec;45(12):1446–1451. PubMed PMID: 24185510; PubMed Central PMCID: PMCPMC4009946. eng. DOI:10.1038/ng.2823
   PubMed Web of Science ®Google Scholar
• Thewes V, Simon R, Schroeter P, et al. Reprogramming of the ERRalpha and ERalpha target gene landscape triggers tamoxifen resistance in breast cancer. Cancer Res. 2015 Feb 15;75(4):720–731. PubMed PMID: 25643697; eng. DOI:10.1158/0008-5472.can-14-0652
   PubMed Web of Science ®Google Scholar
• Yang X, Phillips DL, Ferguson AT, et al. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 2001 Oct 1;61(19):7025–7029. PubMed PMID: 11585728; eng.
   PubMed Web of Science ®Google Scholar
• Ottaviano YL, Issa JP, Parl FF, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994 May 15;54(10):2552–2555. PubMed PMID: 8168078; eng.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct;30(10):870–884. PubMed PMID: 24158787; PubMed Central PMCID: PMCPMC3898123. eng.
   PubMed Web of Science ®Google Scholar
• Finn R, Crown J, Lang I, et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK-4/6 inhibitor), in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) AACR San Diego, CA. 2014; Abstract CT101
   Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25–35. PubMed PMID: 25524798; eng.
   PubMed Web of Science ®Google Scholar
• Finn R, Martin M, Rugo H, et al. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol. 2016;34(suppl; abstr 507).
   Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425–439. PubMed PMID: 26947331; eng.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 May;18(5):654–662. PubMed PMID: 28314691; eng. DOI:10.1016/s1470-2045(17)30109-2
   PubMed Web of Science ®Google Scholar
• Ribociclib FDA (Kisqali). Cited 51517. 2017; March 14. Available online: https://wwwfdagov/drugs/informationondrugs/approveddrugs/ucm546438htm
   Google Scholar
• NCT02102490. A study of abemaciclib (LY2835219) in participants with previously treated breast cancer that has spread (MONARCH1). [cited 2016 Mar 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT02102490?term=ABEMACICLIB&rank=16
   Google Scholar
• Sledge G, Toi M, Neven P, et al. MONARCH2: abemaciclb in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. J Clin Oncol. 2017;35(suppl, abstr 1000).
   Google Scholar
• Yardley DA, Ismail-Khan RR, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013 Jun 10;31(17):2128–2135. PubMed PMID: 23650416; eng. DOI:10.1200/jco.2012.43.7251
   PubMed Web of Science ®Google Scholar
• Andre F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2013 Jul 1;19(13):3693–3702. PubMed PMID: 23658459; eng. DOI:10.1158/1078-0432.ccr-13-0190
   PubMed Web of Science ®Google Scholar
• Musolino A, Campone M, Neven P, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Research: BCR. 2017 Feb 10;19(1):18. PubMed PMID: 28183331; PubMed Central PMCID: PMCPMC5301372. eng. DOI:10.1186/s13058-017-0807-8
   PubMed Web of Science ®Google Scholar
• Soria JC, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014 Nov;25(11):2244–2251. PubMed PMID: 25193991; eng. DOI:10.1093/annonc/mdu390
   PubMed Web of Science ®Google Scholar
• Mayer I, Arteaga C, Nanda R, et al. A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC). Proceedings of the 2016 San Antonio Breast Cancer Symposium; AACR; Cancer Re. 2017;77 (4Suppl): Abstractnr P6-11-03.
   Google Scholar
• Rugo H, Delord J, Im S, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res 2016;76: 4 suppl; abstr S5-07.
   Web of Science ®Google Scholar
• Dirix LY, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76 (suppl 4; abstr S1-04).
   Web of Science ®Google Scholar
• Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011 Nov 20;29(33):4452–4461. PubMed PMID: 22010023; PubMed Central PMCID: PMCPMC3221526. eng. doi:10.1200/jco.2010.34.4879.
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008 Sep 18;27(41):5497–5510. PubMed PMID: 18794884; PubMed Central PMCID: PMCPMC3398461. eng. doi:10.1038/onc.2008.245.
   PubMed Web of Science ®Google Scholar
• Moynahan ME, Chen D, He W, et al. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(-) advanced breast cancer: results from BOLERO-2. Br J Cancer. 2017 Mar 14;116(6):726–730. PubMed PMID: 28183140; PubMed Central PMCID: PMCPMC5355930. eng. DOI:10.1038/bjc.2017.25
   PubMed Web of Science ®Google Scholar
• Vicier C, Dieci MV, Arnedos M, et al. Clinical development of mTOR inhibitors in breast cancer. Breast Cancer Research: BCR. 2014;16(1):203. PubMed PMID: 25189767; PubMed Central PMCID: PMCPMC3978635. eng. DOI:10.1186/bcr3618
   PubMed Web of Science ®Google Scholar
• deGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2004 Dec 1;10(23):8059–8067. PubMed PMID: 15585641; eng. DOI:10.1158/1078-0432.ccr-04-0035
   PubMed Web of Science ®Google Scholar
• Mayer IA. Advanced hormone-sensitive breast cancer: overcoming resistance. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):655–657. PubMed PMID: 25995422; eng.
   PubMed Web of Science ®Google Scholar
• Miller TW, Hennessy BT, Gonzalez-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest. 2010 Jul;120(7):2406–2413. PubMed PMID: 20530877; PubMed Central PMCID: PMCPMC2898598. eng. DOI:10.1172/jci41680
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Kalous O, Conklin D, et al. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat. 2015 Feb;149(3):669–680. PubMed PMID: 25663547; eng. DOI:10.1007/s10549-015-3282-x
   PubMed Web of Science ®Google Scholar
• Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2005 Jul 15;11(14):5319–5328. PubMed PMID: 16033851; eng. DOI:10.1158/1078-0432.ccr-04-2402
   PubMed Web of Science ®Google Scholar
• Ribas R, Pancholi S, Guest SK, et al. AKT antagonist AZD5363 influences estrogen receptor function in endocrine-resistant breast cancer and synergizes with fulvestrant (ICI182780) In Vivo. Mol Cancer Ther. 2015 Sep;14(9):2035–2048. PubMed PMID: 26116361; eng. DOI:10.1158/1535-7163.mct-15-0143
   PubMed Web of Science ®Google Scholar
• Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Research: BCR. 2011;13(2):R21. PubMed PMID: 21362200; PubMed Central PMCID: PMCPMC3219179. eng. DOI:10.1186/bcr2833
   PubMed Web of Science ®Google Scholar
• Wolff AC, Lazar AA, Bondarenko I, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013 Jan 10;31(2):195–202. PubMed PMID: 23233719; PubMed Central PMCID: PMCPMC3532391. eng. DOI:10.1200/jco.2011.38.3331
   PubMed Web of Science ®Google Scholar
• Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer. 2008 Jan;44(1):84–91. PubMed PMID: 18039566; eng. DOI:10.1016/j.ejca.2007.10.003
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, Van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009 Jun 1;27(16):2630–2637. PubMed PMID: 19380449; eng. DOI:10.1200/jco.2008.18.8391
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012 Aug 1;30(22):2718–2724. PubMed PMID: 22565002; eng. DOI:10.1200/jco.2011.39.0708
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520–529. PubMed PMID: 22149876; eng. DOI:10.1056/NEJMoa1109653
   PubMed Web of Science ®Google Scholar
• Andre F. UNIRAD. Randomised, double blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease after receiving at least 1 year of adjuvant hormone therapy. [cited 2016 Jan 30]. Available online at http://www.icr.ac.uk/our-research/our-research-centres/clinical-trials-and-statistics-unit/clinical-trials/unirad
   Google Scholar
• SWOG 1207. Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy ± one year of everolimus in patients with high-risk, hormone receptor-positive and HER2/Neu negative breast cancer. e3 breast cancer study - evaluating everolimus with endocrine therapy. ClinicalTrials.gov Registry Number: NCT01674140. [cited 2016 Jan 30]. Available online at http://swog.org/Visitors/ViewProtocolDetails.asp?ProtocolID=2248
   Google Scholar
• Neoadj ph 2 AI plus everolimus in postmenopausal women w/ER Pos/HER2 neg, low risk score. ClinicalTrials.gov Identifier:NCT02236572. [cited 2016 Jun26]. Available online: https://clinicaltrials.gov/ct2/show/NCT02236572
   Google Scholar
• NCT01698918. Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER1, HER2- metastatic or locally advanced breast cancer (Bolero-4). [cited 2016 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01698918
   Google Scholar
• NCT01783444. A phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in advance breast cancer. (BOLERO-6). [cited 2016 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT01783444
   Google Scholar
• NCT00570921. Study of combined fulvestrant and everolimus in advanced/metastatic breast cancer after aromatase inhibitor failure. (BRE-43). [ cited March 26, 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT00570921
   Google Scholar
• NCT02344550. Study of GnRH plus leterozole +/2 everolimus for premenopausal women with metastatic breast cancer (LEO). [cited 2016 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02344550
   Google Scholar
• NCT02404051. Fulvestrant and EVerolimus Plus EXemestane in metastatic breast cancer (FEVEX). [cited 2016 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02404051
   Google Scholar
• NCT02123823. A phase Ib/II randomized study of BI 836845 in combination with exemestane and everolimus versus exemestane and everolimus alone in women with locally advanced or metastatic breast cancer. [cited 2016 Mar 26]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02123823?term5BI1836845&rank53
   Google Scholar
• Mayer IA, Abramson VG, Isakoff SJ, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20;32(12):1202–1209. PubMed PMID: 24663045; PubMed Central PMCID: PMCPMC3986383. eng. DOI:10.1200/jco.2013.54.0518
   PubMed Web of Science ®Google Scholar
• Baselga J, Im S-A, Iwata H, et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. Cancer Res; Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. 2016;76(4 Suppl):Abstractnr S6-01.
   Google Scholar
• Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):904–916. PubMed PMID: 28576675; eng.
   PubMed Web of Science ®Google Scholar
• Arnedos M, Filleron T, Dieci M, et al. Genomic and immune characterization of metastatic breast cancer (mBC): an ancillary study of the SAFIR01 & MOSCATO trials. Eur Soc Med Oncol. 2014 Abstract 351O
   Google Scholar
• Di Leo A, Seok Lee K, Ciruelos E, et al. BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. Proceedings of the 2016 San Antonio Breast Cancer Symposium. AACR; Cancer Res. 2017;77(4Suppl): Abstractnr S4-07.
   Google Scholar
• Krop I, Johnston S, Mayer I, et al. The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results San Antonio Breast Cancer Symposium Abstract S2-02 2014.
   Google Scholar
• Krop IE, Mayer IA, Ganju V, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Jun;17(6):811–821. PubMed PMID: 27155741; eng. DOI:10.1016/s1470-2045(16)00106-6
   PubMed Web of Science ®Google Scholar
• NCT02437318. Study assessing the efficacy and safety of alpelisib plus fulvestrant in men and postmenopausal women with advanced breast cancer which progressed on or after aromatase inhibitor treatment. (SOLAR-1). [cited 2016 Jun 26]. Available online: https://clinicaltrials.gov/ct2/show/NCT02437318
   Google Scholar
• NCT02340221. SANDPIPER study: a study of taselisib + fulvestrant versus placebo + fulvestrant in patients with advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy. [cited 2016 Mar 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02340221
   Google Scholar
• Dickler M, Saura C, Richards D, et al. A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC). J Clin Oncol. 2016;34(suppl; abstr 520).
   Google Scholar
• Alberts B, Johnson A, Lewis J, et al. Molecular biology of the cell. 4th. New York, NY: Garland Science; 2002.
   Google Scholar
• Dickson MA. Molecular pathways: CDK4 inhibitors for cancer therapy. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2014 Jul 1;20(13):3379–3383. PubMed PMID: 24795392; eng. doi:10.1158/1078-0432.ccr-13-1551.
   PubMed Web of Science ®Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427–1438. PubMed PMID: 15542782; eng.
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Kramer MP. The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications. Expert Opin Investig Drugs. 2011 Dec;20(12):1611–1628. PubMed PMID: 22017180; eng. DOI:10.1517/13543784.2011.628985.
   PubMed Web of Science ®Google Scholar
• Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Jun;18(3):333–345. PubMed PMID: 21367843; PubMed Central PMCID: PMCPMC3624623. eng. DOI:10.1530/erc-10-0262
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 04;490(7418):61–70. PubMed PMID: 23000897; PubMed Central PMCID: PMCPMC3465532. eng. Doi:10.1038/nature11412
   PubMed Web of Science ®Google Scholar
• Prall OW, Sarcevic B, Musgrove EA, et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem. 1997 Apr 18;272(16):10882–10894. PubMed PMID: 9099745; eng.
   PubMed Web of Science ®Google Scholar
• Fry DW, Bedford DC, Harvey PH, et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem. 2001 May 18;276(20):16617–16623. PubMed PMID: 11278443; eng. DOI:10.1074/jbc.M008867200
   PubMed Web of Science ®Google Scholar
• Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014 Jul 15 PubMed PMID: 25028469; Eng. DOI:10.1158/1535-7163.mct-14-0387.
   Web of Science ®Google Scholar
• Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918–925. PubMed PMID: 17363486; eng. DOI:10.1158/1535-7163.mct-06-0613
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Research: BCR. 2009;11(5):R77. PubMed PMID: 19874578; PubMed Central PMCID: PMCPMC2790859. eng. DOI:10.1186/bcr2419
   PubMed Web of Science ®Google Scholar
• Vora SR, Juric D, Kim N, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell. 2014 Jul 14;26(1):136–149. PubMed PMID: 25002028; eng. DOI:10.1016/j.ccr.2014.05.020
   PubMed Web of Science ®Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011 Jun 7;104(12):1862–1868. PubMed PMID: 21610706; PubMed Central PMCID: PMCPMC3111206. eng. DOI:10.1038/bjc.2011.177
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2012 Jan 15;18(2):568–576. PubMed PMID: 22090362; eng. DOI:10.1158/1078-0432.ccr-11-0509
   PubMed Web of Science ®Google Scholar
• DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2015 Mar 01;21(5):995–1001. PubMed PMID: 25501126; eng. DOI:10.1158/1078-0432.ccr-14-2258
   PubMed Web of Science ®Google Scholar
• FDA. Palbociclib. [ cited Feb 12 2015]. Available online. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm
   Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17;375(20):1925–1936. PubMed PMID: 27959613; eng. DOI:10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209–219. PubMed PMID: 26030518; eng. DOI:10.1056/NEJMoa1505270
   PubMed Web of Science ®Google Scholar
• Phase III study of palbociclib (PD-0332991) in combination with exemestane versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL). [cited 2014 May 16] National Institutes of Health Clinical Trials. Available at: http://clinicaltrials.gov/ct2/show/NCT02028507.
   Google Scholar
• PD 0332991 and anastrozole for stage 2 or 3 estrogen receptor positive and HER2 negative breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http://wwwcancergov/clinicaltrials/search/view?cdrid=742660&version=HealthProfessional&protocolsearchid=12773356
   Google Scholar
• A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). National Institutes of Health Clinical Trials. [cited 2014 May 16]. Available at: http://clinicaltrialsgov/show/NCT01864746
   Google Scholar
• Palbociclib + endocrine therapy for HR+ BrCa National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http://wwwcancergov/clinicaltrials/search/view?cdrid=757030&version=HealthProfessional&protocolsearchid=12773356
   Google Scholar
• Mayer E, Gropper A, Tung N, et al. Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: a phase II feasibility study. ASCO Chicago, IL Abstract TPS654. 2014.
   Google Scholar
• NCT02513394. PALbociclib collaborative adjuvant study: a randomized phase III trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (PALLAS). [cited Jul 10 2017]. Available online: https://clinicaltrialsgov/ct2/show/study/NCT02513394?show_locs=Y#locn
   Google Scholar
• Infante J, Shapiro G, Witteveen P, et al. Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas. Mol Cancer Ther. 2013;12:A276.
   Web of Science ®Google Scholar
• Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer: (MONALEESA-2). National Institutes of Health Clinical Trials. Accessed 2014 May 27. Available at: http://clinicaltrials.gov/show/NCT01958021
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016 Nov 03;375(18):1738–1748. PubMed PMID: 27717303; eng. DOI:10.1056/NEJMoa1609709
   PubMed Web of Science ®Google Scholar
• FDA. Kisqali (ribociclib) prescribing information. cited 5 15 17. 2017. Available online: https://wwwaccessdatafda/gov/drugsatfda_docs/label2017/209092s000lblpdf
   Google Scholar
• NCT02422615. Study of efficacy and safety of LEE011 in men and postmenopausal women with advanced breast cancer. (MONALEESA-3). [cited 2017 Jul 16]. Available online: https://clinicaltrialsgov/ct2/show/NCT02422615
   Google Scholar
• NCT02278120. Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7). [ cited Jul. 16.2017]. Available online: https://clinicaltrialsgov/ct2/show/NCT02278120
   Google Scholar
• Cronin-Fenton DP, Damkier P, Lash TL. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107–122. PubMed PMID: 24328412; PubMed Central PMCID: PMCPMC4319217. eng. DOI:10.2217/fon.13.168.
   PubMed Web of Science ®Google Scholar
• Bardia A, Modi S, Chavez-Mac Gregor M, et al. Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2- metastatic breast cancer. ASCO Chicago, IL Abstract 535. 2014.
   Google Scholar
• Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http://www.cancer.gov/clinicaltrials/search/view?cdrid=750319&version=HealthProfessional&protocolsearchid=12773476
   Google Scholar
• Study of LEE011 with fulvestrant and BYL719 or BKM120 in advanced breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. [cited 2014 May 27]. Available at: http://www.cancer.gov/clinicaltrials/search/view?cdrid=759365&version=HealthProfessional&protocolsearchid=12773476
   Google Scholar
• Patnaik A, Rosan LS, Tolaney SM et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer. AACR San Diego, CA Abstract CT232 2014.
   Google Scholar
• Patnaik A, Rosen LS, Tolaney SM et al. LY2835219, a novel cell cycle inhibitor selective for CDK 4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. ASCO Chicago, IL Abstract 534. 2014.
   Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2017 May 22 PubMed PMID: 28533223; eng. DOI:10.1158/1078-0432.ccr-17-0754.
   Web of Science ®Google Scholar
• Sledge GW Jr., Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017 Jun 03:JCO2017737585. PubMed PMID: 28580882; eng. 10.1200/jco.2017.73.7585
   Web of Science ®Google Scholar
• Broderck J Abemaciclib improves PFS in phase III Monarch 3 breast cancer trial. OncLive. 2017; April. [cited 2017 Jul 20]. Available online: http://www.onclive.com/web-exclusives/abemaciclib-improves-pfs-in-phase-iii-monarch-3-breast-cancer-trial
   Google Scholar
• Di Leo A, Toi MCM, Sohn J, et al. MONARCH 3: abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. European Society for Medical Oncology 2017 meeting; Abstract 2360_PR. 2017.
   Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638–3646. PubMed PMID: 28968163; eng. DOI:10.1200/jco.2017.75.6155
   PubMed Web of Science ®Google Scholar
• Hurvitz SM, Fernandez A, Al E. Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer 2016 San Antonio Breast Cancer Symposium Abstract S4-06. 2016.
   Google Scholar
• Rugo H, Tolaney S, Dickler M, et al. A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) Proceedings of the 2016 San Antonio Breast Cancer Symposium; AACR; Cancer Res. 2017;77 (4(Suppl)):Abstractnr OT2-01-07.
   Google Scholar
• Sabnis GJ, Goloubeva O, Chumsri S, et al. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 2011 Mar 1;71(5):1893–1903. PubMed PMID: 21245100; PubMed Central PMCID: PMCPMC3076193. eng. DOI:10.1158/0008-5472.can-10-2458
   PubMed Web of Science ®Google Scholar
• Raha P, Thomas S, Thurn KT, et al. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Research: BCR. 2015;17:26. PubMed PMID: 25848915; PubMed Central PMCID: PMCPMC4367983. eng. DOI:10.1186/s13058-015-0533-z
   PubMed Web of Science ®Google Scholar
• Connolly R, Zhao F, Miller K, et al. E2112: a randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. 2014. San Antonio Breast Cancer Symposium. Abstract OT2-1-06.
   Google Scholar
• Dovitinib plus an aromatase inhibitor for metastatic breast cancer. ClinicalTrials.gov Identifier: NCT01484041. [cited 2016 Jan 31]. Available online at: https://clinicaltrials.gov/show/NCT01484041
   Google Scholar
• NCT02053636. A phase II trial testing oral administration of lucitanib in patients with fibroblast growth factor receptor (FGFR)1-amplified or non-amplified estrogen receptor positive metastatic breast cancer (FINESSE). [cited 2016 Jun 27]. Available online: https://clinicaltrials.gov/ct2/show/NCT02053636
   Google Scholar
• Nanda R, Liu MC, C As Y, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. J Clin Oncol 2017;35:15_suppl (May 2017) 506–506.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017 Aug 24;548(7668):471–475. PubMed PMID: 28813415; PubMed Central PMCID: PMCPMC5570667. eng. DOI:10.1038/nature23465
   PubMed Web of Science ®Google Scholar
• NCT01823835. A study of GDC-0810 single agent or in combination with palbociclib and/or a luteinizing hormone-releasing hormone (LHRH) agonist in women with locally advanced or metastatic estrogen receptor positive breast cancer. Accessed online: ClinicalTrials gov 111017
   Google Scholar
• Cochrane DR, Bernales S, Jacobsen BM, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research: BCR. 2014 Jan 22;16(1):R7. PubMed PMID: 24451109; PubMed Central PMCID: PMCPMC3978822. eng. DOI:10.1186/bcr3599
   PubMed Web of Science ®Google Scholar
• NCT02007512. Efficacy and safety study of enzalutamide in combination with exemestane in patients with advanced breast cancer. Available online: ClinicalTrialsgov Accessed 111017.
   Google Scholar
• Yardley DAKI, Abramson V, Colleoni M, et al. Results from a randomized placebo-controlled phase 2 trial evaluating exemestane +/- enzalutamide in patients with hormone receptor positive breast cancer. San Antonio Breast Cancer Symposium Abstract GS4-07. 2017; December.
   Google Scholar
• Dickler MN, Barry WT, Cirrincione CT, et al.Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 Aug 01;34(22):2602–2609. PubMed PMID: 27138575; PubMed Central PMCID: PMCPMC5012690 online at . contributions are found at the end of this article. eng. 10.1200/jco.2015.66.1595
   PubMed Web of Science ®Google Scholar
• Martin M, Loibl S, Von Minckwitz G, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015 Mar 20;33(9):1045–1052. PubMed PMID: 25691671; eng. DOI:10.1200/jco.2014.57.2388
   PubMed Web of Science ®Google Scholar
• Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014 Jun;4(6):650–661. PubMed PMID: 24801577; PubMed Central PMCID: PMCPMC4433544. eng. DOI:10.1158/2159-8290.cd-13-1014.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Linton KM, Cervi P, et al. A clinician’s guide to biosimilars in oncology. Cancer Treat Rev. 2016 May;46:73–79. PubMed PMID: 27135548; eng. DOI:10.1016/j.ctrv.2016.04.003
   PubMed Web of Science ®Google Scholar